Navigating Diagnostic and Therapeutic Challenges in Primary Cutaneous Gamma/Delta T-Cell Lymphoma: A Case Study of Fatal Outcomes Within Two Months.


Journal

The American Journal of dermatopathology
ISSN: 1533-0311
Titre abrégé: Am J Dermatopathol
Pays: United States
ID NLM: 7911005

Informations de publication

Date de publication:
01 Sep 2024
Historique:
medline: 16 8 2024
pubmed: 16 8 2024
entrez: 16 8 2024
Statut: ppublish

Résumé

Primary cutaneous gamma/delta T-cell lymphoma (PCGD-TCL) is a rare yet highly aggressive subtype of primary cutaneous lymphoma. Characterized by its challenging diagnosis and poor prognosis, PCGD-TCL presents unique clinical and histopathological features that distinguish it from other primary cutaneous lymphoma subtypes. Here, we report the case of a 75-year-old man who initially presented with multiple erythematous indurated plaques over his back and bilateral lower extremities. The initial biopsy suggested primary cutaneous T-cell lymphoma (PCTCL) with a CD30-negative phenotype. However, within a 2-month interval, the disease progressed rapidly, manifesting as extensive skin involvement across the chest and upper extremities. A repeat skin biopsy was performed, revealing dermal atypical lymphocytes without epidermotropism. Immunohistochemical analysis demonstrated positivity for CD3, CD5, and CD4, as well as T-cell receptor delta (TCR delta) expression, along with the loss of CD8 and CD30 expression. These findings were consistent with a diagnosis of PCGD-TCL. Despite therapeutic interventions, including systemic treatments, the patient's condition deteriorated rapidly, ultimately leading to his demise within a month of receiving the PCGD-TCL diagnosis. This case highlights the diagnostic complexities associated with PCGD-TCL, emphasizing the importance of careful histopathological examination and immunophenotypic characterization. Given its aggressive nature and propensity for rapid dissemination, early recognition of PCGD-TCL is paramount for initiating appropriate therapeutic interventions. However, effective treatment options for PCGD-TCL remain limited, and the disease typically carries an unfavorable prognosis. Further research is needed to elucidate the underlying molecular mechanisms driving the pathogenesis of PCGD-TCL, to identify novel therapeutic targets, and to improve patient outcomes. In addition, increased awareness among clinicians and pathologists regarding the clinical presentation and diagnostic criteria of PCGD-TCL is crucial for facilitating timely diagnosis and management of this challenging malignancy.

Identifiants

pubmed: 39150181
doi: 10.1097/DAD.0000000000002743
pii: 00000372-202409000-00006
doi:

Substances chimiques

Receptors, Antigen, T-Cell, gamma-delta 0
Biomarkers, Tumor 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

593-596

Informations de copyright

Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Merrill ED, Agbay R, Miranda RN, et al. Primary cutaneous T-cell lymphomas showing gamma-delta (γδ) phenotype and predominantly epidermotropic pattern are clinicopathologically distinct from classic primary cutaneous γδ T-cell lymphomas. Am J Surg Pathol. 2017;41:204–215.
Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703–1714.
Willemze R. Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification. Presse Med. 2022;51:104126.10.1016/j.lpm.2022.104126
doi: 10.1016/j.lpm.2022.104126
Geller S, Myskowski PL, Pulitzer M, et al. Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature. Chin Clin Oncol. 2019;8:5.
von Dücker L, Fleischer M, Stutz N, et al. Primary cutaneous gamma-delta T-cell lymphoma with long-term indolent clinical course initially mimicking lupus erythematosus profundus. Front Oncol. 2020;10:133.
Rodríguez-Pinilla SM, Ortiz-Romero PL, Monsalvez V, et al. TCR-γ expression in primary cutaneous T-cell lymphomas. Am J Surg Pathol. 2013;37:375–384.
Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas-An update 2021. Hematol Oncol. 2021;39(suppl 1):46–51.
Ramani NS, Curry JL, Merrill ED, et al. Primary cutaneous gamma-delta (γ/δ) T-cell lymphoma: an unusual case with very subtle histopathological findings. Am J Dermatopathol. 2016;38:e147–e149.
Goyal A, Nardi V. Gamma/delta (γδ) T cells: the role of the T-cell receptor in diagnosis and prognosis of hematologic malignancies. Am J Dermatopathol. 2022;44:237–248.
Muhsen IN, El Fakih R, Hamadani M, et al. Clinical, diagnostic and prognostic characteristics of primary cutaneous gamma delta T-cell lymphomas. Clin Hematol Int. 2022;4:1–10.
Oh Y, Stoll JR, Moskowitz A, et al. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: prognosis and management. J Am Acad Dermatol. 2021;85:1093–1106.
Tran J, Vega F, Duvic M. Unmasking a T cell lymphoma: folliculotropic mycosis fungoides with a gamma-delta phenotype. JAAD Case Rep. 2020;6:1316–1319.
Jour G, Aung PP, Merrill ED, et al. Differential expression of CCR4 in primary cutaneous gamma/delta (γ⁄δ) T cell lymphomas and mycosis fungoides: significance for diagnosis and therapy. J Dermatol Sci. 2018;89:88–91.
Torres-Cabala CA, Huen A, Iyer SP, et al. Gamma/delta phenotype in primary cutaneous T-cell lymphomas and lymphoid proliferations: challenges for diagnosis and classification. Surg Pathol Clin. 2021;14:177–194.
Vin H, Talpur R, Tetzlaff MT, et al. T-cell receptor-γ in gamma-delta phenotype cutaneous T-cell lymphoma can be accompanied by atypical expression of CD30, CD4, or TCRβF1 and an indolent clinical course. Clin Lymphoma Myeloma Leuk. 2014;14:e195–e200.
Guitart J, Chung C, Torres-Cabala CA. The dilemma of primary γδ epidermotropic T-cell lymphoma: distinction from mycosis fungoides, signs of cytotoxicity, and need for more detailed analysis. J Cutan Pathol. 2022;49:419–420.
Tomasini D, Croci GA, Hotz A, et al. Gamma/delta T-cell lymphoma with mycosis fungoides-like clinical course transforming to “T-cell-receptor-silent” aggressive lymphoma: description of one case. J Cutan Pathol. 2021;48:1197–1203.
Hirata C, Nakai K, Kurasawa Y, et al. Primary cutaneous gamma-delta T-cell lymphoma initially diagnosed as subcutaneous panniculitis-like T-cell lymphoma with dermatomyositis. Dermatopathology (Basel). 2022;9:143–147.
Haghayeghi K, Patel D, Rice SM, et al. Primary cutaneous gamma-delta T-cell lymphoma masquerading as leukemia cutis in a patient recently diagnosed with small lymphocytic lymphoma: clues to the diagnosis. J Cutan Pathol. 2022;49:1015–1020.
Cocks M, Porcu P, Wick MR, et al. Recent advances in cutaneous T-cell lymphoma: diagnostic and prognostic considerations. Surg Pathol Clin. 2019;12:783–803.
Lozzi GP, Massone C, Citarella L, et al. Rimming of adipocytes by neoplastic lymphocytes: a histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol. 2006;28:9–12.
Kempf W, Kazakov DV, Scheidegger PE, et al. Two cases of primary cutaneous lymphoma with a γ/δ+ phenotype and an indolent course: further evidence of heterogeneity of cutaneous γ/δ+ T-cell lymphomas. Am J Dermatopathol. 2014;36:570–577.

Auteurs

Nada Shaker (N)

Department of Pathology, The Ohio State University Wexner Medical Center/James Cancer Hospital, Columbus, OH.

Heath Blankenship (H)

Department of Pathology and Dermatology, Wake Forest University, School of Medicine, Medical Center Boulevard, Winston-Salem, NC; and.

Vaishali Masatkar (V)

Department of Pathology and Dermatology, Wake Forest University, School of Medicine, Medical Center Boulevard, Winston-Salem, NC; and.

Shuo Niu (S)

Department of Pathology, Wake Forest University, School of Medicine, Medical Center Boulevard, Winston-Salem, NC.

Omar P Sangueza (OP)

Department of Pathology and Dermatology, Wake Forest University, School of Medicine, Medical Center Boulevard, Winston-Salem, NC; and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH